Orchestra BioMed Holdings, Inc.
OBIO
$4.49
-$0.08-1.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12,120.16% | -12.77% | 7.46% | 40.00% | -3.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12,120.16% | -12.77% | 7.46% | 40.00% | -3.44% |
| Cost of Revenue | -12.07% | -27.94% | 4.55% | 29.41% | 23.40% |
| Gross Profit | 15,728.72% | -11.64% | 7.63% | 40.61% | -9.30% |
| SG&A Expenses | 23.52% | 25.27% | -3.14% | 6.21% | 41.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.72% | 22.19% | 14.32% | 31.55% | 32.86% |
| Operating Income | 140.50% | -24.30% | -14.64% | -31.19% | -33.62% |
| Income Before Tax | 138.66% | -35.02% | -21.17% | -39.31% | -26.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 138.66% | -35.02% | -21.17% | -39.31% | -26.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 138.66% | -35.02% | -21.17% | -39.31% | -26.03% |
| EBIT | 140.50% | -24.30% | -14.64% | -31.19% | -33.62% |
| EBITDA | 141.20% | -24.38% | -14.66% | -31.28% | -33.72% |
| EPS Basic | 122.79% | 2.66% | -12.97% | -30.35% | -16.34% |
| Normalized Basic EPS | 123.75% | 2.69% | -13.14% | -30.80% | -31.14% |
| EPS Diluted | 122.79% | 2.66% | -12.97% | -30.35% | -16.34% |
| Normalized Diluted EPS | 123.75% | 2.69% | -13.14% | -30.80% | -31.14% |
| Average Basic Shares Outstanding | 62.80% | 38.71% | 7.24% | 6.87% | 8.32% |
| Average Diluted Shares Outstanding | 62.80% | 38.71% | 7.24% | 6.87% | 8.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |